Enanta's hepatitis C drug candidate designated as a 'breakthrough therapy'

A combination treatment regimen for hepatitis C in trials at AbbVie, which uses a drug candidate developed by Enanta Pharmaceuticals Inc., , has received Breakthrough Therapy designation from the U.S. Food and Drug Administration , qualifying it for potentially faster approval.

http://www.bizjournals.com/boston/blog/bioflash/2013/05/enantas-hepatitis-c-drug-candidate.html?ana=RSS&s=article_search&utm_source=feedburner&utm_medium=feed&utm_campaign=Feed%3A+vertical_38+%28Health+Care+Regulation+Industry+News%29